CGRP Antagonists: How Anti-CGRP Drugs Stop Migraines
Substance P and Pain
50%+ fewer migraines
CGRP-targeting drugs reduce monthly migraine days by 50% or more in clinical trials, the first migraine-specific preventive treatment class in decades.
Zhu et al., meta-analysis, 2018
Zhu et al., meta-analysis, 2018
View as imageMigraine treatment was stuck for decades. Patients relied on triptans for acute attacks and repurposed drugs (beta-blockers, antidepressants, anticonvulsants) for prevention, none of which were designed for migraine. That changed with the discovery that calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, is a central driver of migraine pathophysiology. Blocking CGRP or its receptor has produced the first class of migraine-specific preventive treatments, and they work.[1] For a broader view of how pain-signaling peptides including CGRP and substance P interact, see the pillar article on substance P and pain.
A 2018 meta-analysis of randomized controlled trials found that CGRP monoclonal antibodies reduced monthly migraine days significantly more than placebo, with response rates (50% or greater reduction) consistently exceeding those of older preventive treatments.[2] Seven drugs targeting this pathway are now approved for migraine in various countries.
Key Takeaways
- CGRP is released from trigeminal nerve endings during migraine and causes vasodilation, neurogenic inflammation, and pain signal amplification (Edvinsson, 2018)
- Four monoclonal antibodies target CGRP or its receptor: erenumab (receptor), fremanezumab, galcanezumab, and eptinezumab (all target the peptide itself)
- Three small-molecule gepants block the CGRP receptor orally: rimegepant, ubrogepant, and atogepant
- Meta-analysis of RCTs showed CGRP antibodies reduced episodic migraine days by 1.5-2.0 per month more than placebo, with 50% responder rates of 40-60% (Zhu et al., 2018)
- The 2024 American Headache Society consensus recommends CGRP-targeting drugs as first-line migraine prevention
- Safety data from the first three years of clinical use shows mild injection-site reactions and constipation as the most common side effects, with rare reports of Raynaud's phenomenon (Alex et al., 2020)
Why CGRP matters in migraine
CGRP is the most abundant neuropeptide in the trigeminal system, the sensory nerve network that innervates the head, face, and meninges. During a migraine attack, activated trigeminal neurons release CGRP into the perivascular space around meningeal blood vessels. This triggers a cascade: dilation of meningeal arteries, mast cell degranulation, release of additional inflammatory mediators, and sensitization of pain-transmitting neurons.[3]
The evidence for CGRP's role is layered across multiple lines. Jugular venous blood samples taken during migraine attacks show elevated CGRP levels that normalize as the attack resolves. Intravenous infusion of CGRP triggers migraine-like headaches in migraine-susceptible individuals but not in controls. Triptans, which effectively abort migraine attacks, reduce CGRP release from trigeminal neurons. And genetic studies have identified CGRP pathway variants associated with migraine risk.[4]
A 2018 update on the pharmacology of the calcitonin/CGRP peptide family by Hay et al. detailed the receptor biology: CGRP binds to a heterodimeric receptor complex consisting of calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 1 (RAMP1).[5] This receptor is expressed on smooth muscle cells in meningeal arteries, on trigeminal ganglion neurons, and in brainstem pain-processing centers. The multi-site expression means CGRP blockade can interrupt migraine at peripheral, ganglionic, and central levels.
The monoclonal antibody revolution
The development of anti-CGRP monoclonal antibodies represented a conceptual breakthrough: rather than treating migraine symptoms after they start, these drugs prevent attacks by persistently blocking CGRP signaling.
Erenumab (Aimovig) was the first approved in 2018. It is unique among the four antibodies because it targets the CGRP receptor rather than the CGRP molecule itself. This means it blocks all CGRP signaling at the receptor, regardless of whether the CGRP comes from local release or circulating sources. Administered as a monthly subcutaneous injection (70 mg or 140 mg).[6]
Fremanezumab (Ajovy) targets the CGRP molecule directly, binding both alpha and beta isoforms. It offers flexible dosing: 225 mg monthly or 675 mg quarterly, making it the only CGRP antibody with a three-month dosing option.[6]
Galcanezumab (Emgality) also binds the CGRP ligand. It requires a 240 mg loading dose followed by 120 mg monthly injections. It is additionally approved for episodic cluster headache, the only CGRP antibody with this indication.[7]
Eptinezumab (Vyepti) is the only intravenous CGRP antibody, administered as a 100 mg or 300 mg infusion every three months. Its IV route means faster onset of action compared to subcutaneous formulations, with some patients reporting benefit within the first week.[6]
A 2017 comparison across randomized controlled trials found that all four antibodies produced statistically significant reductions in monthly migraine days compared to placebo, with no clear superiority of one over another in indirect comparisons.[8]
Gepants: oral CGRP receptor antagonists
While monoclonal antibodies require injection, small-molecule CGRP receptor antagonists (gepants) can be taken orally. The first-generation gepants (olcegepant, telcagepant) were effective but shelved due to liver toxicity concerns. The current generation solved that problem.
Rimegepant (Nurtec ODT) is approved for both acute migraine treatment and prevention, a dual indication unique among CGRP drugs. For prevention, it is taken every other day (75 mg orally disintegrating tablet). For acute treatment, a single dose during an attack can reduce headache within two hours.[9]
Ubrogepant (Ubrelvy) is approved only for acute migraine treatment (50 mg or 100 mg). It represents an alternative to triptans for patients who cannot tolerate or do not respond to serotonin agonists.
Atogepant (Qulipta) is approved only for migraine prevention (10 mg, 30 mg, or 60 mg daily). It is the first oral CGRP antagonist designed specifically for preventive use.
Berman et al. (2020) demonstrated that rimegepant can be safely combined with CGRP monoclonal antibodies, an important finding for patients with refractory migraine who need both preventive and acute CGRP-targeting treatments.[9]
What the clinical trial data shows
The efficacy data comes from large, well-conducted randomized controlled trials.
For episodic migraine (4-14 headache days per month), the 2018 meta-analysis by Zhu et al. pooled data across multiple trials and found CGRP antibodies reduced monthly migraine days by 1.5 to 2.0 days more than placebo.[2] The 50% responder rate (proportion of patients whose migraine frequency dropped by half or more) ranged from 40% to 62% across trials, compared to 20-38% for placebo.
For chronic migraine (15+ headache days per month), the benefit was more pronounced in absolute terms because patients had more days to improve. CGRP antibodies reduced monthly headache days by 2.0 to 4.5 days more than placebo in chronic migraine populations.
The European Headache Federation guideline by Sacco et al. (2019) synthesized this evidence and recommended CGRP-targeting treatments for patients who had failed at least two conventional preventive medications.[10] By 2024, the American Headache Society updated its position to recommend CGRP-targeting drugs as first-line preventive treatment, removing the requirement for prior treatment failures.
Quality of life improvements accompany the migraine day reductions. Torres-Ferrus et al. (2019) conducted a pooled analysis showing that CGRP antibodies significantly improved scores on migraine-specific quality of life questionnaires, disability scales, and work productivity measures.[11]
Receptor target vs ligand target: does it matter?
The distinction between erenumab (receptor-targeting) and the other antibodies (ligand-targeting) has theoretical implications.
Receptor-targeting blocks all CGRP signaling at that receptor, including from CGRP-related peptides like amylin and adrenomedullin that share receptor components. This could be broader in effect but also broader in side effects. Ligand-targeting specifically neutralizes circulating CGRP without affecting other peptides that use overlapping receptor machinery.
In practice, head-to-head trials comparing receptor versus ligand approaches are limited. Khan et al. (2019) reviewed the available clinical data and found no consistent difference in efficacy or tolerability between the two approaches.[12] The choice between drugs is more often driven by dosing preference (monthly vs quarterly, subcutaneous vs IV) than by target specificity.
This pharmacological distinction does matter for the broader understanding of the calcitonin peptide family. The CGRP and migraines article covers the basic science of how CGRP was identified as a migraine target.
Safety: what three years of real-world data shows
The safety profile of CGRP-targeting drugs has been scrutinized intensively because CGRP has physiological roles beyond migraine. It is a potent vasodilator in coronary and cerebral arteries, it participates in wound healing, and it may provide cardioprotective effects during ischemia.
Alex et al. (2020) conducted a retrospective safety analysis of the first three CGRP monoclonal antibodies in clinical practice.[13] The most common adverse events were injection-site reactions (pain, redness, swelling), constipation (particularly with erenumab), and upper respiratory infections. These were generally mild and rarely led to treatment discontinuation.
More concerning but rare reports included Raynaud's phenomenon (painful vasoconstriction in the fingers), which was initially reported as case series. Evans (2019) documented Raynaud's episodes associated with CGRP antibody use, hypothesizing that blocking CGRP's vasodilatory function in peripheral arteries could unmask or worsen Raynaud's in susceptible individuals.[13] This remains a theoretical concern under investigation rather than a common side effect.
Cardiovascular safety is the most important unresolved question. CGRP protects against ischemia-reperfusion injury in animal models, and blocking it raises the concern of increased cardiovascular risk during events like myocardial infarction or stroke. Clinical trials excluded patients with recent cardiovascular events, so the safety data in high-risk populations is limited. Long-term registry data is accumulating but remains insufficient for definitive conclusions.
How CGRP drugs compare to traditional prevention
The arrival of CGRP-targeting therapies has changed the migraine treatment landscape. Hargreaves and Olesen (2019) reviewed the history and noted that CGRP drugs represent the first mechanism-based migraine preventive treatments, in contrast to older approaches that were discovered serendipitously.[14]
Compared to topiramate, propranolol, or amitriptyline, CGRP-targeting drugs offer better tolerability (fewer cognitive, cardiovascular, and weight side effects), more convenient dosing (monthly or quarterly injection vs daily pills), and comparable or superior efficacy for patients with frequent episodic or chronic migraine. The trade-off is cost: CGRP drugs are significantly more expensive than generic preventive medications. A month of topiramate costs under $20 in generic form, while a monthly CGRP antibody injection runs $600-700 before insurance. This cost differential has influenced guidelines: the European recommendation for CGRP drugs after two prior treatment failures reflects cost-effectiveness calculations, while the American first-line recommendation reflects the clinical superiority data without equivalent weight on pharmacoeconomics.
For patients who respond, the value proposition is clear. Migraine costs the US economy over $36 billion annually in lost productivity and healthcare expenses. Reducing migraine frequency by 50% or more can return patients to functional baseline in ways that partially effective older medications often cannot.
For patients interested in the broader peptide biology of pain signaling, the articles on conotoxins and pain medicine and venom-derived peptide analgesics cover other peptide-based approaches to pain management.
The Bottom Line
CGRP-targeting drugs represent the most significant advance in migraine treatment in decades. Four monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) and three oral gepants (rimegepant, ubrogepant, atogepant) block CGRP signaling through different mechanisms. Clinical trials consistently show 50% or greater migraine frequency reduction in 40-62% of treated patients. Safety data from the first years of clinical use is reassuring, with constipation and injection-site reactions as the most common side effects. The main unresolved questions involve long-term cardiovascular safety and optimal patient selection between the multiple available agents.